Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
出版年份 2022 全文链接
标题
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-08-24
DOI
10.1186/s12933-022-01572-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
- (2022) Alison K. Wright et al. DIABETES CARE
- Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
- (2022) Irene Caruso et al. Metabolites
- Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure
- (2022) Annalisa Sforza et al. Cardiovascular Diabetology
- Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
- (2021) Elisabetta Patorno et al. DIABETES CARE
- Lower risk of death and cardiovascular events in patients with diabetes initiating GLP ‐1 receptor agonists or SGLT ‐2 inhibitors: a real‐world study on two Italian cohorts
- (2021) Marta Baviera et al. DIABETES OBESITY & METABOLISM
- Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
- (2021) Moa Lugner et al. Cardiovascular Diabetology
- SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
- (2021) Sheyu Li et al. BMJ-British Medical Journal
- Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
- (2021) Christina E. DeRemer et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study
- (2021) Reimar W. Thomsen et al. Journal of the American Heart Association
- Cardiovascular Outcomes with GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Patients with Type 2 Diabetes
- (2021) Caroline H Nørgaard et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
- (2021) Elisabetta Patorno et al. ANNALS OF INTERNAL MEDICINE
- Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
- (2021) Andrea Natali et al. Cardiovascular Diabetology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- SGLT-2 inhibitors as cardio-renal protective agents
- (2021) Irene Caruso et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms
- (2021) Jennifer Y. Barraclough et al. Cells
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- (2020) Enrico Longato et al. BMJ Open Diabetes Research & Care
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
- (2019) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
- (2019) Francesco Giorgino et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Drug Derived Complexity Index (DDCI) Predicts Mortality, Unplanned Hospitalization and Hospital Readmissions at the Population Level
- (2016) Fabio Robusto et al. PLoS One
- Why do we need observational studies of everyday patients in the real-life setting?: Table 1
- (2015) Alexander T. Cohen et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
- (2010) Que Liu et al. Cardiovascular Diabetology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More